Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antagonists of the bradykinin B1 receptor

a technology of bradykinin and b1 receptor, which is applied in the field of anti-bradykinin b1 receptor antagonists, can solve the problems of life style alteration, debilitating and/or dangerous side effects, ulceration, bleeding, etc., and achieves the effect of superior pharmacokinetic properties

Inactive Publication Date: 2009-02-19
AMGEN INC
View PDF18 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, current treatments for pain are only partially effective, and many also cause life-style altering, debilitating, and / or dangerous side effects.
For example, non-steroidal anti-inflammatory drugs (“NSAIDs”) such as aspirin, ibuprofen, and indomethacin are moderately effective against inflammatory pain but they are also renally toxic, and high doses tend to cause gastrointestinal irritation, ulceration, bleeding, increased cardiovascular risk, and confusion.
Local anesthetics such as lidocaine and mixelitine simultaneously inhibit pain and cause loss of normal sensation.
In addition, when used systemically local anesthetics are associated with adverse cardiovascular effects.
Thus, there is currently an unmet need in the treatment of chronic pain.
However, certain types of tissue damage cause a phenomenon, known as hyperalgesia or pronociception, in which relatively innocuous stimuli are perceived as intensely painful because the person's pain thresholds have been lowered.
Similarly, trauma, surgery, amputation, abscess, causalgia, collagen vascular diseases, demyelinating diseases, trigeminal neuralgia, cancer, chronic alcoholism, stroke, thalamic pain syndrome, diabetes, herpes infections, acquired immune deficiency syndrome (“AIDS”), toxins and chemotherapy cause nerve injuries that result in excessive pain.
While a variety of peptide antagonists targeting the B1 receptor have been identified, their development as therapeutic analgesics has been stymied by poor efficacious half-lives resulting from very rapid degradation by tissue and serum peptidases and efficient renal clearance.
PEGylation of small therapeutic peptides, on the other hand, presents unique challenges and has not been broadly applied.
One of the greatest obstacles to peptide PEGylation is the essential requirement that biological activity be preserved in the final conjugate.
Because therapeutic peptides often comprise the minimal sequence required for activity and are therefore very small, they are relatively intolerant to substitution.
Thus, a peptide's ability to tolerate PEGylation and still retain sufficient specific activity to be a useful therapeutic is quite unpredictable and must be empirically determined (Morpurogo, et al., Selective Alkylation and Acylation of α and ε Amino Groups with PEG in a Somatostatin Analogue: Tailored Chemistry for Optimized Bioconjugates.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antagonists of the bradykinin B1 receptor
  • Antagonists of the bradykinin B1 receptor
  • Antagonists of the bradykinin B1 receptor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis and Purification of B1 Receptor Peptide Antagonists and PEG-Conjugated B1 Receptor Peptide Antagonists

[0224]Various peptides of the invention were synthesized using synthesis techniques well-known in the art. A preferred method of synthesizing various peptides of the invention uses a FMOC strategy with carbodiimide activation as described below.

[0225]Part 1: Dissolve Fmoc-Amino Acid to Resin Using Carbodiimide Chemistry.

[0226]Fmoc-amino acid (3-4 equivalent) was dissolved in dry DCM / NMP mixture (NMP or DMF was used to aid complete dissolution). A solution of N-hydroxybenzotriazole (HOBt, same equivalent to amino acid) in NMP was added to the amino acid solution. A solution of N,N′-dicyclohexyl-carbodiimide (DCC, same equivalent to amino acid) in DCM was added to the amino acid solution. The solution was mixed for approximately 20 minutes. The activated acid solution was then added to resin (if needed, precipitates were removed prior to addition). The reaction was agitated ...

example 2

Synthesis and Purification of PEG-Conjugated B1 Receptor Peptide Antagonists Using PEG Thioesters

[0246]PEG-conjugated peptides were prepared by reacting a cysteine containing peptide with PEG-maleimide in 50 mM NaHPO4, 5 mM EDTA, pH 7 at 2.5-5 mg / ml peptide and a reaction stoichiometry of 1.2-fold molar excess of maleimide:thiol. The reaction was stirred at room temperature (20-25° C.) for 18-26 hours. Once complete, the reaction is quenched with a 10-fold molar excess of β-mercaptoethanol (β-ME):maleimide and allowed to stir an additional 30-60 minutes at room temperature. The reactions were purified as described for Method A in Example 1 above.

example 3

Synthesis and Purification of PEG-Conjugated B1 Receptor Peptide Antagonists Using PEG Thioesters or Iodoacetates

[0247]PEG-conjugated peptides were prepared by reacting peptide containing a N-terminal cysteine residue with PEG-OPTE (ortho-pyridyl thio ester) in 50 mM NaHPO4, 5 mM EDTA, pH 7 at 2.5-5 mg / ml peptide and a reaction stoichiometry of 1.2-fold molar excess of activated PEG:peptide. The reaction was stirred at room temperature (20-25° C.) for 18-26 hr. Once complete, the reaction is quenched with a 10-fold molar excess of cysteine:excess PEG reagent and allowed to stir an additional 30-60 minutes at room temperature. The reactions were purified as described in Method A of Example 1 above.

[0248]Alternatively, PEG-iodoacetamide may be used as described above to form conjugates in which the PEG moiety is attached via a thioether linkage (Scheme 3). In this case 1.5 molar equivalents of the activated PEG reaction is used and the reaction time is increased to 24 hours the reacti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular massaaaaaaaaaa
strengthaaaaaaaaaa
thresholdaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method of treating, preventing, or ameliorating a disease or condition associated with or mediated by B1 activity that involves administering a composition of matter containing bradykinin B1 receptor antagonist peptides conjugated to a multivalent vehicle, including peptides conjugated to multivalent PEG. The method can be used therapeutically or prophylactically against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.

Description

[0001]This application is a division of U.S. patent application Ser. No. 10 / 972,236, filed Oct. 21, 2004, which claims the benefit of U.S. Provisional Application No. 60 / 513,913 filed Oct. 22, 2003, and U.S. Provisional Application No. 60 / 538,929 filed Jan. 24, 2004, which are hereby incorporated by reference in their entireties.BACKGROUND OF THE INVENTION[0002]More than two million people in the United States alone are incapacitated by chronic pain on any given day (T. M. Jessell & D. D. Kelly, Pain and Analgesia in PRINCIPLES OF NEURAL SCIENCE, third edition (E. R. Kandel, J. H. Schwartz, T. M. Jessell, ed., (1991)). Unfortunately, current treatments for pain are only partially effective, and many also cause life-style altering, debilitating, and / or dangerous side effects. For example, non-steroidal anti-inflammatory drugs (“NSAIDs”) such as aspirin, ibuprofen, and indomethacin are moderately effective against inflammatory pain but they are also renally toxic, and high doses tend ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/08A61K38/02A61P29/00A61P25/00A61P11/06A61K38/10A61K47/48C07K7/06C07K7/08C07K7/18
CPCA61K38/08A61K38/10C07K7/18C07K7/08C07K7/06A61P1/02A61P1/04A61P11/00A61P11/02A61P11/06A61P13/00A61P13/10A61P15/00A61P17/00A61P17/02A61P17/04A61P17/06A61P17/16A61P19/02A61P19/04A61P21/00A61P25/00A61P25/02A61P25/04A61P25/06A61P25/32A61P27/02A61P29/00A61P29/02A61P31/18A61P31/22A61P35/00A61P37/06A61P37/08A61P43/00A61P7/00A61P9/00A61P3/10A61K38/043A61K47/10
Inventor NG, GORDONLI, YUE-SHENGGEGG, COLIN V.ASKEW, JR., BENNY C.STORZ, THOMASLU, YUELIED'AMICO, DERIN C.JAROSINSKI, MARK A.LIU, CHUAN-FAHUANG, QI
Owner AMGEN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products